L3VLUP
ProSign in

LLY · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

LLYVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • LLY
  • VRTX
0204060202120222023202420252026
Holders and value by quarter
QuarterLLYVRTX
Q3 202033 holders, $14.1bn31 holders, $21.9bn
Q4 202029 holders, $17.3bn30 holders, $18.4bn
Q1 202124 holders, $23.0bn31 holders, $15.4bn
Q2 202124 holders, $27.8bn30 holders, $12.7bn
Q3 202131 holders, $29.9bn35 holders, $10.1bn
Q4 202131 holders, $34.7bn28 holders, $12.4bn
Q1 202224 holders, $35.3bn23 holders, $16.1bn
Q2 202233 holders, $42.7bn25 holders, $18.1bn
Q3 202231 holders, $43.4bn22 holders, $18.4bn
Q4 202231 holders, $46.6bn28 holders, $18.4bn
Q1 202333 holders, $44.3bn26 holders, $21.4bn
Q2 202337 holders, $59.6bn27 holders, $24.7bn
Q3 202344 holders, $67.6bn33 holders, $24.3bn
Q4 202345 holders, $73.6bn32 holders, $28.6bn
Q1 202441 holders, $95.3bn31 holders, $29.8bn
Q2 202443 holders, $110bn29 holders, $33.4bn
Q3 202445 holders, $107bn27 holders, $33.5bn
Q4 202446 holders, $93.9bn26 holders, $28.5bn
Q1 202542 holders, $98.4bn21 holders, $35.4bn
Q2 202543 holders, $93.2bn21 holders, $32.3bn
Q3 202539 holders, $86.7bn22 holders, $25.9bn
Q4 202541 holders, $123bn26 holders, $31.8bn
Q1 202639 holders, $106bn25 holders, $31.8bn
Q2 202644 holders, $132bn26 holders, $34.6bn
LLY

Eli Lilly & Co

Holders
42
Reported value
$98.4bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$35.4bn
Buyers
10
Sellers
11

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only LLY (24)

Acadian Asset Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Egerton Capital UK LLP, Eisler Capital Management Ltd, GAMCO Investors Inc, Holocene Advisors LP, Lone Pine Capital LLC, Man Group PLC, Point72 Asset Management LP, Polen Capital Management LLC, Schonfeld Strategic Advisors LLC, Tiger Global Management LLC, Tudor Investment Corp, Two Sigma Advisers LP, Verition Fund Management LLC, Winton Group Ltd

Only VRTX (3)

ARK Investment Management LLC, Baillie Gifford & Co, PDT Partners LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →